A Gleason score of 6 is the lowest score assigned to prostate cancer, and it indicates the least aggressive form of the disease. It falls into what’s called Grade Group 1, the most favorable category in prostate cancer grading. For most men who receive this result, the cancer grows slowly, carries a very low risk of spreading, and often doesn’t require immediate treatment.
That said, seeing the word “cancer” on a pathology report is alarming regardless of the number next to it. Understanding what a Gleason 6 actually looks like under a microscope, how it behaves, and what happens next can help put the diagnosis in perspective.
How the Gleason Score Works
When a pathologist examines prostate biopsy tissue, they look at how the cells are organized and assign two pattern scores, each ranging from 3 to 5. The first number represents the most common pattern in the sample, and the second represents the next most common. These two numbers are added together to produce the Gleason score. A score of 6 (written as 3+3) means both patterns show the most well-organized, least abnormal architecture possible.
In a Gleason pattern 3, the glands still form individual, well-defined structures. They may vary in size and shape, and some may branch or pack closely together, but each gland remains discrete and recognizable. This is a key distinction from higher-grade patterns (4 and 5), where glands fuse together, lose their structure, or disappear entirely. The organized architecture of pattern 3 reflects a cancer that is slow-growing and behaves in a fundamentally different way from higher-grade disease.
How Gleason 6 Cancer Behaves
Gleason 6 prostate cancer has an exceptionally favorable prognosis. A major clinical trial comparing active monitoring, surgery, and radiation for localized prostate cancer found that after 10 years, death rates from the cancer were approximately 1% across all three groups. In other words, the vast majority of men with low-grade prostate cancer survive the disease regardless of which management path they choose.
Perhaps the most reassuring finding comes from studies of men who had their prostates surgically removed. Among those whose surgical specimens showed exclusively Gleason 6 cancer, none developed metastatic disease within 10 years. This has led some experts to argue that true Gleason 6 tumors simply do not spread to other parts of the body. About 5% of Gleason 6 cancers grow slightly beyond the prostate itself, but even this rarely translates into life-threatening progression.
The Upgrade Question
One important caveat: a biopsy samples only a small portion of the prostate. A needle can miss a more aggressive area sitting nearby. Studies show that roughly 20% of men initially diagnosed with Gleason 6 on biopsy are found to have higher-grade cancer when the prostate is later examined more thoroughly, either through a repeat biopsy or after surgery. This doesn’t mean the Gleason 6 cells themselves became more dangerous. It means the original biopsy didn’t capture the full picture.
This sampling limitation is a major reason why ongoing monitoring matters. The roughly 2% of men with a Gleason 6 biopsy who eventually develop metastatic disease likely had a higher-grade component that was missed initially. Modern MRI-guided biopsies have improved the accuracy of initial grading, but the possibility of an upgrade is something your care team will watch for over time.
Active Surveillance: The Preferred Approach
For most men with Gleason 6 prostate cancer, the recommended approach is active surveillance rather than immediate treatment. This isn’t “doing nothing.” It’s a structured monitoring program designed to catch any change in the cancer early enough to treat it if needed, while avoiding the side effects of surgery or radiation for a cancer that may never cause harm.
A typical active surveillance schedule includes:
- PSA blood tests every six months to track changes in prostate-specific antigen levels
- Physical exam no more than once a year
- MRI scans and repeat biopsies every one to two years initially, then less frequently if results remain stable
The trend in recent years has been to rely more on MRI and less on frequent biopsies. If yearly MRI scans and PSA levels show no changes, many centers now space biopsies out to every two to three years. The goal is to minimize the discomfort and infection risk of repeated biopsies while still keeping close tabs on the cancer.
Active surveillance is the preferred strategy for men with very low-risk prostate cancer who have a life expectancy of 10 years or more. It’s also an option for men with favorable intermediate-risk disease, though the monitoring may be more intensive in those cases.
What Triggers a Shift to Treatment
If a follow-up biopsy shows that the cancer has been upgraded to Gleason 7 or higher, or if MRI reveals significant growth, the conversation shifts toward active treatment. The most common options at that point are surgery to remove the prostate or radiation therapy. Because active surveillance catches these changes early, men who do eventually need treatment are typically still candidates for a cure.
Rising PSA levels alone don’t necessarily mean the cancer is progressing. PSA can fluctuate for many reasons, including benign prostate enlargement or inflammation. Your care team looks at the overall trend across multiple tests, not a single reading, before recommending any change in approach.
Why Some Experts Question the “Cancer” Label
There is ongoing debate among specialists about whether Gleason 6 should even be called cancer. Because it virtually never metastasizes when it’s truly the only grade present, some urologists and pathologists have argued that the label causes unnecessary fear and leads some men to pursue aggressive treatment they don’t need. The counterargument is that Gleason 6 cells do look abnormal under a microscope, and the label ensures patients take monitoring seriously.
Regardless of where individual experts fall in this debate, the practical takeaway is the same: a Gleason 6 diagnosis is not an emergency. It’s a slow-moving condition that, for most men, can be safely monitored for years or even decades without treatment. The risk comes not from the Gleason 6 cells themselves, but from the small chance that a more aggressive cancer was missed on biopsy, which is exactly what active surveillance is designed to detect.